Preclinical investigations reveal that FHD-286 promotes chromatin compaction, inhibits oncogenic regulators such as c-Myc and PU.1, and diminishes leukemia-initiating potential in acute myeloid leukemia (AML) models [254]. This evidence concerns the gene SPI1 and acute myeloid leukemia.